BPC-157 vs NAD+

BPC-157 is believed to accelerate angiogenesis and upregulate growth hormone receptors locally at injury sites. It appears to promote fibroblast migration and collagen synthesis, contributing to faster tissue remodelling. Animal studies suggest systemic effects via modulation of the dopaminergic and serotonergic systems, though human data remain limited.

BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. It is commonly researched for its role in soft tissue repair, particularly in tendons, ligaments, and muscle following injury or high training loads. Early research suggests it may also support gut integrity and systemic healing.

NAD+ is a coenzyme central to cellular energy metabolism, serving as an electron carrier in glycolysis, the citric acid cycle, and oxidative phosphorylation. It is also a required substrate for sirtuins (SIRT1–7) and PARP enzymes, which regulate DNA repair, gene expression, and mitochondrial biogenesis. NAD+ levels decline measurably with age; IV or subcutaneous delivery aims to restore intracellular pools more directly than oral precursors such as NMN or NR.

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every cell, central to energy production, DNA repair, and sirtuin activation. While not a peptide in the traditional sense, it is widely administered by functional medicine and longevity providers via intravenous infusion or subcutaneous injection. Research interest centres on its role in mitochondrial health, cellular resilience, and neurological function as NAD+ levels decline with age.